Dr Lucy Yates | Clinician Scientist Fellow

Yates, Lucy

Lucy Yates is a Wellcome Trust Clinical Career Development Fellow.  She uses cutting-edge genomic technologies to explore the evolutionary basis of clinical cancer progression.   

My research to date has focused on defining the genomic basis of breast cancer, intra-tumour heterogeneity and the evolutionary patterns underlying metastasis. My current work draws on novel genomic technologies such as in-situ sequencing and single-cell combined genomic and transcriptomic sequencing (G&T-seq). I am using these approaches to understand why some very early breast tumours transform into invasive cancers while others remain indolent and to explore how, after primary treatment some breast cancers are able to enter an undetectable (dormant or sleeping) state for decades prior to reappearing in a more aggressive form. My ultimate aim is to translate this biological knowledge into better treatments for people living with cancer.

Publications

  • Genomic Evolution of Breast Cancer Metastasis and Relapse.

    Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S et al.

    Cancer cell 2017;32;2;169-184.e7

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G et al.

    Nature medicine 2015;21;7;751-9

  • The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

    Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2018;29;1;30-35

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

  • Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.

    Yates LR and Desmedt C

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017;23;11;2630-2639

  • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

    Davies H, Glodzik D, Morganella S, Yates LR, Staaf J et al.

    Nature medicine 2017;23;4;517-525

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

    Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D et al.

    Nature 2016;534;7605;47-54

  • Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

    de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC et al.

    Science (New York, N.Y.) 2014;346;6206;251-6

  • Evolution of the cancer genome.

    Yates LR and Campbell PJ

    Nature reviews. Genetics 2012;13;11;795-806

  • The landscape of cancer genes and mutational processes in breast cancer.

    Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C et al.

    Nature 2012;486;7403;400-4

  • Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes.

    Yates L, Kirby A, Crichton S, Gillett C, Cane P et al.

    International journal of radiation oncology, biology, physics 2012;82;5;2093-103

  • Pan-cancer analysis of whole genomes.

    ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium

    Nature 2020;578;7793;82-93

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

  • The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

    Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2018;29;1;30-35

  • Genomic Evolution of Breast Cancer Metastasis and Relapse.

    Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S et al.

    Cancer cell 2017;32;2;169-184.e7

  • Intratumoral heterogeneity and subclonal diversification of early breast cancer.

    Yates LR

    Breast (Edinburgh, Scotland) 2017

  • Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.

    Yates LR and Desmedt C

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017;23;11;2630-2639

  • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

    Davies H, Glodzik D, Morganella S, Yates LR, Staaf J et al.

    Nature medicine 2017;23;4;517-525

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

    Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D et al.

    Nature 2016;534;7605;47-54

  • Catalog of genetic progression of human cancers: breast cancer.

    Desmedt C, Yates L and Kulka J

    Cancer metastasis reviews 2016;35;1;49-62

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G et al.

    Nature medicine 2015;21;7;751-9

  • Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

    Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR et al.

    Genome research 2015;25;6;814-24

  • Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

    de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC et al.

    Science (New York, N.Y.) 2014;346;6206;251-6

  • Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

    Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL et al.

    Science (New York, N.Y.) 2014;345;6196;1251343

  • Processed pseudogenes acquired somatically during cancer development.

    Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I et al.

    Nature communications 2014;5;3644

  • Signatures of mutational processes in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S et al.

    Nature 2013;500;7463;415-21

  • Evolution of the cancer genome.

    Yates LR and Campbell PJ

    Nature reviews. Genetics 2012;13;11;795-806

  • The landscape of cancer genes and mutational processes in breast cancer.

    Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C et al.

    Nature 2012;486;7403;400-4

  • Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes.

    Yates L, Kirby A, Crichton S, Gillett C, Cane P et al.

    International journal of radiation oncology, biology, physics 2012;82;5;2093-103

  • Ultra low dose thalidomide in elderly patients with myeloma.

    Bowcock SJ, Minchom A, Yates LR and Ryali MM

    British journal of haematology 2008;141;1;120-2

Yates, Lucy
Lucy's Timeline
2019

Honorary Consultant Clinical Oncologist | Guy's and St Thomas' NHS Trust

Wellcome Clinical Career Development Fellowship

2016

PhD Wellcome Sanger Institute and University of Cambridge

Fellow of The Royal College of Radiologists

2008

NCRI Academic Clinical Fellow | Guy's, Kings and St Thomas' NHS Trust